Evaluation of HLA-G, HLA-E, and PD-L1 proteins in oral osteosarcomas

被引:22
作者
Costa Arantes, Diego Antonio [1 ]
Goncalves, Andreia Souza [1 ]
Jham, Bruno Correia [2 ]
Barroso Duarte, Eliza Carla [3 ]
de Paula, Elbio Candido [4 ]
de Paula, Henrique Moura [4 ,5 ]
Mendonca, Elismauro Francisco [1 ,6 ]
Batista, Aline Carvalho [1 ]
机构
[1] Univ Fed Goias, Sch Dent, Dept Stomatol Oral Pathol, Goiania, Go, Brazil
[2] Midwestern Univ, Coll Dent Med Illinois, Downers Grove, IL 60515 USA
[3] Univ Brasilia, Sch Med, Dept Pathol, Brasilia, DF, Brazil
[4] Assoc Canc Combat Goias, Araujo Jorge Hosp, Div Anat Pathol, Goiania, Go, Brazil
[5] Univ Fed Goias, Sch Med, Dept Pathol & Med Lab, Goiania, Go, Brazil
[6] Assoc Canc Combat Goias, Araujo Jorge Hosp, Head & Neck Div, Goiania, Go, Brazil
来源
ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY | 2017年 / 123卷 / 06期
关键词
SQUAMOUS-CELL CARCINOMA; PROGRAMMED DEATH LIGAND-1; TUMOR MICROENVIRONMENT; PROGNOSTIC-FACTORS; UNTREATED MELANOMA; ANTIBODY BLOCKADE; CANCER PATIENTS; IMMUNE ESCAPE; NECK SARCOMAS; LUNG-CANCER;
D O I
10.1016/j.oooo.2016.12.002
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
Objective. The aim of this study was to investigate the expression of human leukocyte antigens (HLAs) G and E and programmed death-ligand 1 (PD-L1) in oral osteosarcoma (OO) (n = 13). The relationship between the expression of these molecules and histologic grading and metastasis was also evaluated. Study Design. HLA-G, HLA-E, and PD-L1 were identified by immunohistochemistry. Samples of normal bone tissue (n = 6) were used as controls. The sections were evaluated using a semiquantitative scoring system with an immunoreactive score, where a score of 0 was considered absent, <= 2 was low, and > 2 was high expression. Results. We identified high expression of HLA-G, HLA-E, and PD-L1 by malignant osteoblastic cells in 69.2% of OO cases, which was statistically higher than that in controls (P < .05). Overexpression of these proteins was identified in 8 of 11 samples of high-grade and 1 of 2 samples of low-grade OO. Additionally, 66.6% of patients with metastases (n = 4) and 71.4% of patients without metastases (n = 5) had high expression of HLA-G, HLA-E, and PD-L1 in tumor samples (P > .05). Conclusion. OO had high expression of HLA-G, HLA-E, and PD-L1 irrespective of clinicopathologic parameters, including histologic grading and metastasis.
引用
收藏
页码:E188 / E196
页数:9
相关论文
共 62 条
[1]   Malignant orofacial neoplasms in children and adolescents: A clinicopathologic review of cases in a Nigerian tertiary hospital [J].
Ajayi, Oluseyi Folake ;
Adeyemo, Wasiu Lanre ;
Ladeinde, Akinola Ladipo ;
Ogunlewe, Mobolante Olugbemiga ;
Omitola, Olufemi Gbenga ;
Effiom, Olajumoke Ajibola ;
Arotiba, Godwin Toyin .
INTERNATIONAL JOURNAL OF PEDIATRIC OTORHINOLARYNGOLOGY, 2007, 71 (06) :959-963
[2]  
Alishahi B, 2015, IRAN J CANCER PREV, V8, DOI 10.17795/ijcp-3432
[3]   Serum Soluble HLA-E in Melanoma: A New Potential Immune-Related Marker in Cancer [J].
Allard, Mathilde ;
Oger, Romain ;
Vignard, Virginie ;
Percier, Jean-Michel ;
Fregni, Giulia ;
Perier, Aurelie ;
Caignard, Anne ;
Charreau, Beatrice ;
Bernardeau, Karine ;
Khammari, Amir ;
Dreno, Brigitte ;
Gervois, Nadine .
PLOS ONE, 2011, 6 (06)
[4]  
Azizi T., 2009, Indian Journal of Cancer, V46, P231, DOI 10.4103/0019-509X.52958
[5]   Grade of chemotherapy-induced necrosis as a predictor of local and systemic control in 881 patients with non-metastatic osteosarcoma of the extremities treated with neoadjuvant chemotherapy in a single institution [J].
Bacci, G ;
Mercuri, M ;
Longhi, A ;
Ferrari, S ;
Bertoni, F ;
Versari, M ;
Picci, P .
EUROPEAN JOURNAL OF CANCER, 2005, 41 (14) :2079-2085
[6]   Predictive Impact of Common Variations in DNA Repair Genes on Clinical Outcome of Osteosarcoma [J].
Bai, Sheng-Bin ;
Chen, Hong-Xiang ;
Bao, Yong-Xing ;
Luo, Xue-Gang ;
Zhong, Jin-Jie .
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2013, 14 (06) :3677-3680
[7]   The fourth modality: immunotherapy for head and neck cancer hits pay dirt [J].
Bell, R. Bryan .
ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY, 2016, 121 (06) :575-577
[8]   Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].
Borghaei, H. ;
Paz-Ares, L. ;
Horn, L. ;
Spigel, D. R. ;
Steins, M. ;
Ready, N. E. ;
Chow, L. Q. ;
Vokes, E. E. ;
Felip, E. ;
Holgado, E. ;
Barlesi, F. ;
Kohlhaeufl, M. ;
Arrieta, O. ;
Burgio, M. A. ;
Fayette, J. ;
Lena, H. ;
Poddubskaya, E. ;
Gerber, D. E. ;
Gettinger, S. N. ;
Rudin, C. M. ;
Rizvi, N. ;
Crino, L. ;
Blumenschein, G. R. ;
Antonia, S. J. ;
Dorange, C. ;
Harbison, C. T. ;
Finckenstein, F. Graf ;
Brahmer, J. R. .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639
[9]   Recognition of human histocompatibility leukocyte antigen (HLA)-E complexed with HLA class I signal sequence-derived peptides by CD94/NKG2 confers protection from natural killer cell-mediated lysis [J].
Borrego, F ;
Ulbrecht, M ;
Weiss, EH ;
Coligan, JE ;
Brooks, AG .
JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 187 (05) :813-818
[10]   HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C [J].
Braud, VM ;
Allan, DSJ ;
O'Callaghan, CA ;
Söderström, K ;
D'Andrea, A ;
Ogg, GS ;
Lazetic, S ;
Young, NT ;
Bell, JI ;
Phillips, JH ;
Lanier, LL ;
McMichael, AJ .
NATURE, 1998, 391 (6669) :795-799